Boston Scientific Microwave BPH Pact Follows Tech Investment Strategy
This article was originally published in The Gray Sheet
Executive Summary
Boston Scientific's equity investment in microwave benign prostatic hyperplasia (BPH) therapy developer Celsion, including worldwide distribution rights, could lead to an outright purchase of the technology